伦敦初创公司Baseimmune近日在A轮融资中取得重大突破，成功吸引了1130万美元（约900万英镑）的投资，用于进一步开发其创新的疫苗设计机器学习平台。这次融资活动超额认购，彰显了投资者对Baseimmune技术潜力的强烈信心。参与本轮融资的知名投资方包括MSD Global Health Innovation Fund、IQ Capital，以及早期支持Baseimmune的Hoxton Ventures、Creator Fund、Beast Ventures和Maki.vc。
Baseimmune致力于利用人工智能技术简化疫苗设计过程，其独特的机器学习平台有望彻底改变疫苗研发领域。这笔资金的注入将加速公司的研发进度，推动其技术在实际应用中发挥更大的作用，为全球公共卫生带来革命性的解决方案。
此次融资的成功，不仅为Baseimmune提供了充足的财务支持，同时也为其在全球生物技术和医疗健康领域树立了更强的影响力。Baseimmune表示，将利用这笔资金加强研发团队，优化现有技术，并积极推进与业界合作伙伴的联合研发项目，以期早日将人工智能驱动的疫苗设计带入临床实践。
Baseimmune的创新模式和科技实力，无疑为全球疫苗研发开辟了新的路径，此次融资的成功预示着公司在未来将有更大的发展空间，我们期待他们为全球健康事业带来更多的突破性成果。
英语如下：
News Title: “London Biotech Startup Baseimmune Secures $11.3 Million Investment, AI Vaccine Design Platform Garners Attention”
Keywords: Baseimmune, AI疫苗, Funding of $11.3 million
News Content: London-based startup Baseimmune has recently made a significant stride in its Series A funding round, successfully attracting $11.3 million (approximately £9 million) to further develop its innovative vaccine design platform powered by machine learning. The oversubscribed round underscores investors’ strong confidence in Baseimmune’s technological potential. Esteemed investors participating in this round include MSD Global Health Innovation Fund, IQ Capital, as well as early supporters Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc.
Dedicated to simplifying vaccine design using artificial intelligence, Baseimmune’s unique machine learning platform is poised to revolutionize the vaccine development landscape. The influx of funds will accelerate the company’s research and development进程, enabling its technology to have a more significant impact on global public health.
This successful funding not only provides Baseimmune with substantial financial backing but also strengthens its influence in the global biotech and healthcare sectors. The company intends to utilize the funds to expand its research team, refine existing technologies, and actively pursue collaborative R&D projects with industry partners, aiming to expedite the clinical application of AI-driven vaccine design.
Baseimmune’s innovative approach and technological prowess open new avenues in global vaccine research. The funding success foreshadows substantial growth potential for the company, and we look forward to their groundbreaking contributions to global health initiatives.
【来源】https://www.maginative.com/article/baseimmune-closes-11-3m-series-a-to-accelerate-ai-designed-vaccines/
Views: 1